Hodgkin Lymphoma

I don’t think we have good data to show re use of I/O post failure adds much in Hodgkins In lung and kidney we have negative studies in this space (@BijoyTelivala)

A multicentre analysis of ACOPP for older/less fit patients with Hodgkin lymphoma. Promising efficacy and deliverability providing an option for this challenging clinical scenario https://t.co/S0DaILQOeI @mattwilson2287 @pammckay123 @wendster #lymsm @DrAEvens @BritSocHaem (@BrJHaem)

🗣️:🇹🇷/👥:👨‍⚕️🩸🦀 🤔 Aynı çalışma farklı solid organ tümörleri yada hematolojik malignitelerde flow sitometri kullanılarak daha kolayca yapılabilir. İyi bir makale çıkarabilecek bir konu bence. Hodgkin lenfoma konusunda şimdiden heyecanlandım. Teşekkürler. (@Dr_MSU)

Dr. @ravivij Discussing with @timfenske on #HodgkinLymphoma (HL) at @mycancerhaven https://t.co/PdzRpQkEJm Get Full access to the video by Signing Up at https://t.co/XIinFH8pLB Thankyou So much for joining with us @timfenske 🙏 (@My_Cancer_Haven)

I was the second room.. Hodgkins 3A Deauville 1 on last two post chemo scans. Thx for what you, and maybe more importantly, the infusion chemo nurses do and all the staff. (@Montuckster)

El-Galaly TC, Glimelius I. Late relapses in Hodgkin lymphoma - should we search for the needle in the haystack? Br J Haematol. 2022 Jul;198(1):11-13. doi: 10.1111/bjh.18199. Epub 2022 Apr 19. PMID: 35438825; PMCID: PMC9324958. (@glimelius)

Not perfect but: Glimelius I et al Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics. Am J Hematol. 2015 Dec;90(12):1128-34. doi: 10.1002/ajh.24184. Epub 2015 Oct 6. PMID: 26349012. (@glimelius)

And a review we wrote on this with also some Swedish results: Glimelius I, Diepstra A. Novel treatment concepts in Hodgkin lymphoma. J Intern Med. 2017 Mar;281(3):247-260. doi: 10.1111/joim.12582. Epub 2016 Dec 19. PMID: 27991731. (@glimelius)

Biccler JL, Glimelius I, Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study. J Clin Oncol. 2019 Mar 20;37(9):703-713. doi: 10.1200/JCO.18.01652. Epub 2019 Feb 6. (@glimelius)

Yes, lots of Swedish #Hodgkin data, what in particular, published articles or datasets? (@glimelius)

And No increased relapse risk after pregnancy 😊 Weibull CE, ….Glimelius I. Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma. J Clin Oncol. 2016 Feb 1;34(4):337-44. doi: 10.1200/JCO.2015.63.3446. Epub 2015 Dec 14. PMID: 26668344. (@glimelius)

🙌Looking forward to a v. informative @ASH_hematology education session on #HodgkinLymphoma at #ASH23 in sunny San Diego! 👉Also look forward to highlighting 2 fantastic #lymphoma experts, Dr. @MDAndersonNews Dr @sairah__ahmed & @UNC_Lineberger @NatalieGroverMD. @WomenInLymphoma (@DrAEvens)

O @samaritanohosp realiza hoje, 05 de julho, às 19h, uma discussão multidisciplinar sobre o tema ‘Linfoma de Hodgkin Predominância Linfocitária Nodular: um linfoma mais complexo do que parece’ - https://t.co/viCTbg3qHo @CarlosChiattone @GuiperiniMD @pinotti_camila @TomasBarrese (@PortalOnconews)

Popcorn cell in Hodgkin Lymphoma (@Macchiato1986)

Only age, 60s, and her family history of other sister with Hodgkin and relapse after using her full match brother. Thank you all for your help! (@E_D_Bezerra)

Thank you much! No single mismatched unrelated donor options. We usually would prefer haplo and that’s what we lean towards, but her family history ( her sister also with Hodgkin and relapse after MRD from brother) raised the question of a familiar non measurable factor. (@E_D_Bezerra)

32F relapsed Hodgkin after MRD, mild chronic GvHD, no response to ICI, brentuximab or jakafi, now CR after Gem-Benda, which graft you pick? Sister who was not her donor also had hodgkin. Negative genetic eval. No MUD or MMUD. @matthew_mei @timfenske @MediHumdani @DrMiguelPerales (@E_D_Bezerra)

Das gute Beacopp eskaliert. Ich war auch genau zu dieser Jahreszeit vor 5 Jahren damit fertig. Hodgkin Stadium 4b war's bei mir. Bin in Ihrem Alter. Ich wünsche Ihnen ein gutes Resultat und eine gute Rehabilitation! (@AlexanderZeitb1)

Relapsed Hodgkins If patient has progressed on single agent Nivo please don’t switch them to single agent Pembro Use something else @nihardesai7 @PallawiTorkaMD (@BijoyTelivala)

Any data in hodgkin lymphoma? Frontline cpi+chemo efficacy was fasnicating last asco and eha but any significant sign in vte? (@kirkizlar)

You don't have to change my mind. Just do the best you can to help me. #cancersurvivor @CancerAdvocacy @NCICancerSurv #hodgkins #CancerCareMASCC (@HodgkinsIntl)

PD-1 refractory or stable Hodgkin disease patients had response to nivolumab combination with ruxolitinib (@SabarishMD)

Tracked roots of Sir Thomas Hodgkin - @DrGPrakash #bedford #GauravPrakash #lymphoma #kingscollege #pilgrimage #ThomasHodgkin #cancer #oncology #oncodaily https://t.co/43YeRrBZVC (@oncodaily)

Tomorrow on #HealthcareUnfiltered, Alex Herrera of ⁦@cityofhope⁩ shares his inspiring story that started years before he stood up at the ⁦@ASCO⁩ #ASCO23 presenting practice-changing Hodgkin data. Here’s a clip; no he’s not on twitter despite ⁦@montypal⁩ efforts. (@chadinabhan)

Great points Andy. Certainly can’t be said that Hodgkin research has no questions now to answer! (@graham74GC)

There was a ton of hodgkins data… more than Ive ever seen 🙏🏻 (@DrPaulyDeSantis)

CMV infection may still present similar signs/symptoms with Hodgkin's. (@taribokuro)

So proud to present #260 poster on postASCT maint in Hodgkin lymphoma Big collaborative effort of 14 US and Czech centers. Sanjal Desai @umnmedschool deserves credit! #17ICML (@vit_prochazka)

#17ICML Lymphocyte predominant International Prognostic Score (LP-IPS) #lymsm (@DrRaulCordoba)

Falini - dual targeting CD30 / PDL1 CAR-T for Hodgkin • current CD30 CAR-T, responses not durable • CD30 present at relapse, ?due to immunosupp microenv • mouse models suggest PDL1 / CD30 dual target improve long term response Watch this space! #17ICML (@graham74GC)

Wanted to briefly thank you Dr. Younes. 15 yrs ago I came to you for a consult about my refractory hodgkins. Survival was very uncertain. you were very transparent & thoughtful, ultimately steering me towards a trial offered by another clinician/institution. Today I’m cured. TY! (@Lowell)

Hodgkin Lyphoma! We have come a long way! Check out our new paper on “Classical Hodgkin Lymphoma - From Past to Future…” Grateful to our team in compiling this comprehensive review. @ShaikhaQ14 @CuglievanBranko @MDPIOpenAccess @IJMS_MDPI @MDAndersonNews https://t.co/IXMMvDGWA8 (@FaryalMunir6)

Distinct molecular determinants of treatment-failure in elderly Hodgkin lymphoma identified by cell-free DNA profiling: A LYSA Study #PhasEDSeq @LysaLymphoma Cedric Rossi @StefanAlig @schroersmartin @mohamshah @max_diehn @TakeshiSugio @nonoscherlebeck https://t.co/L3jAtonN85 (@AshAlizadeh)

R Küppers: Hodgkin biology. No matter how many times heard, always learn something new. Today e.g. about: Generation of bi-/multi nucleated RS cells. Refusion of daughter cells from Hodgkin cells. CD30 activating MYC. Role of BCR in NLPHL. Mutated IRF4 in HRS cells. #17ICML (@Dr_Daniel_Molin)

#17ICML . We are gonna start with challenge cases Hodgkin lymphoma and T-cell lymphoma (@hematologo)

Nice Hodgkin case discussion. Notably @PWMJohnson would treat a young pt w stage IIIB with esc BEACOPDac, rather than RATHL. #17ICML (@Dr_Daniel_Molin)

#17ICML This Thursday . ARE WE REACHING THE MAXIMUM CURE RATE FOR HODGKIN LYMPHOMA? By Peter Johnson MD. You don’t miss it. https://t.co/4qhSb5mRVt (@hematologo)

DISTINCT HODGKIN LYMPHOMA SUBTYPES IDENTIFIED BY NONINVASIVE GENOMIC PROFILING @StefanAlig @mohamshah @michaelsbinkley @schroersmartin @Rcl14L @BCCancer @JamieFlerlage @SharonCastelli2 @COGorg @max_diehn @theNCI @DeptofDefense @Krebshilfe_Bonn #LYSARC https://t.co/FBX1XwEhLF (@AshAlizadeh)

@AnnaSureda5 addresses the challenges in older patients with #Hodgkin #lymphoma #lymsm #geriheme #17ICML (@DrRaulCordoba)

#17ICML S Borchmann gives an excellent talk about new biomarkers in #Hodgkin #lymphoma and introduces a new PET-CT measure: Dmax, maximum distance between lesions, with a poorer prognostic factor when >20cm #lymsm (@DrRaulCordoba)

Great talk from @graham74GC on a great window study in Hodgkin co-led with @DrElizaHawkes #lymsm #ICML2023 (@mike_dickinson1)

#17ICML A Moskowitz presents data on geriatric assessment in older patients with #Hodgkin #lymphoma receiving N-AVD. Very happy to see CGA at least baseline before initiating chemotherapy #lymsm #geriheme (@DrRaulCordoba)